Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Teva
QuintilesIMS
Chinese Patent Office
Baxter
Argus Health
Fish and Richardson
Federal Trade Commission
Covington

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206334

« Back to Dashboard
NDA 206334 describes ORBACTIV, which is a drug marketed by The Medicines Co and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the ORBACTIV profile page.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.

Summary for NDA: 206334

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:5

Suppliers and Packaging for NDA: 206334

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION) 206334 NDA The Medicines Company 65293-015 65293-015-03 3 VIAL, GLASS in 1 CARTON (65293-015-03) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (65293-015-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)StrengthEQ 400MG BASE/VIAL
Approval Date:Aug 6, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 6, 2024
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Aug 6, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Nov 24, 2017Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Citi
Cantor Fitzgerald
Novartis
Dow
Mallinckrodt
AstraZeneca
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot